

# Rebecca A G Christensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/101895/publications.pdf>

Version: 2024-02-01

20  
papers

324  
citations

1162889

8  
h-index

887953

17  
g-index

21  
all docs

21  
docs citations

21  
times ranked

343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study. <i>Journal of Obesity</i> , 2021, 2021, 1-6.	1.1	9
2	The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0250508.	1.1	30
3	Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. <i>International Journal of Obesity</i> , 2021, 45, 1687-1695.	1.6	4
4	The association of sex and calendar month with changes in weight: A retrospective cohort study of a community-based weight management clinic. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 515-517.	0.8	1
5	Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feeding. <i>Nutrition</i> , 2021, 91-92, 111393.	1.1	2
6	Time-Restricted Eating: A Novel and Simple Dietary Intervention for Primary and Secondary Prevention of Breast Cancer and Cardiovascular Disease. <i>Nutrients</i> , 2021, 13, 3476.	1.7	15
7	Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic. <i>Journal of Obesity</i> , 2021, 2021, 1-8.	1.1	5
8	The safety and effectiveness of commonly-marketed natural supplements for weight loss in populations with obesity: A critical review of the literature from 2006 to 2016. <i>Critical Reviews in Food Science and Nutrition</i> , 2020, 60, 1614-1630.	5.4	26
9	Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. <i>Obesity Science and Practice</i> , 2020, 6, 439-444.	1.0	17
10	Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program. <i>Obesity Science and Practice</i> , 2020, 6, 382-389.	1.0	4
11	Four Dates, One Future. <i>University of Toronto Journal of Public Health</i> , 2020, 1, .	0.0	0
12	Effectiveness of a Community-Based Weight Management Program for Patients Taking Antidepressants and/or Antipsychotics. <i>Obesity</i> , 2019, 27, 1539-1544.	1.5	1
13	Response to Liraglutide Effectiveness: Is There a Real-World Clinical Benefit? <i>Obesity</i> , 2019, 27, 1728-1728.	1.5	0
14	Absolute Weight Loss, and Not Weight Loss Rate, Is Associated with Better Improvements in Metabolic Health. <i>Journal of Obesity</i> , 2019, 2019, 1-6.	1.1	4
15	Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. <i>Clinical Obesity</i> , 2019, 9, e12323.	1.1	83
16	Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada. <i>Obesity</i> , 2019, 27, 917-924.	1.5	50
17	The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review. <i>Journal of Drug Assessment</i> , 2019, 8, 184-191.	1.1	5
18	Medications that cause weight gain and alternatives in Canada: a narrative review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 427-438.	1.1	57

#	ARTICLE	IF	CITATIONS
19	Weight loss medications in Canada &ndash;&nbsp;a new frontier or a repeat of past mistakes?. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 413-417.	1.1	9
20	Using real-world transaction data to identify money laundering: Leveraging traditional regression and machine learning techniques. STEM Fellowship Journal, 0, , 1-11.	0.5	2